Medical AI is not like a chat app you can patch overnight. Once a tool is in clinics, the risk is what happens after approval—when models drift, workflows change, or real patients meet the software.
On 6 October 2026, the UK government said it will accept all 44 recommendations of the National Commission into the Regulation of AI in Healthcare, and the Medicines and Healthcare products Regulatory Agency (MHRA) opened applications for AI Airlock Phase 3. [1]
What the government committed to
The commission’s report was published on 10 September. In its response, the government commits to lifecycle-based, proportionate regulation of AI as a medical device—meaning oversight that follows a product through use, not only a one-off green light. [1]
Near-term milestones named in the government announcement include:
- MHRA draft guidance by December 2026 on managing changes to AI devices
- Consultation next year on qualifying and classifying AI-enabled devices
- A full implementation roadmap by Spring 2027
What is AI Airlock Phase 3?
AI Airlock is the MHRA’s regulatory sandbox—a supervised space where developers and regulators can test how rules work on real products. Phase 3 focuses on post-market surveillance and lifecycle regulation: watching how AI medical devices behave after they are in use, not only before they ship. [1]
According to the government news release, a webinar is set for 22 October 2026, the first wave of participants is due to be selected in November 2026, and three years of additional funding has been secured. [1]
Why this is more than a press release
Full acceptance of a doctors-led commission, paired with a live sandbox wave aimed at post-market monitoring, marks a concrete UK shift: from treating AI medical devices as static products toward continuous oversight. For hospitals and vendors, the practical upshot is clearer expectations—eventually—on how to update models without flying blind.
What we don’t know
- Accepting recommendations is not the same as passing new statute; draft guidance and the Spring 2027 roadmap still have to land.
- How the devolved nations will implement the same direction will evolve through joint work; details are not fixed in this announcement alone.
- Which products enter Airlock Phase 3’s first wave will only become clear after November selection.
The Bottom Line
Britain has backed every recommendation from its doctors-led healthcare AI commission and opened MHRA Airlock Phase 3 around post-market surveillance. The direction is clear—regulate AI medical tools across their whole life—while the binding rules and timelines for clinics still depend on the guidance and roadmap still to come.
Sources
- GOV.UK, 6 October 2026 — https://www.gov.uk/government/news/government-backs-recommendations-of-nhs-doctors-led-ai-commission
